PHAXIAM Therapeutics (PHXM) 6-K 20 Sep 21 2021 Q2 I.Certification of the Person Responsible for the Half-year Financial Report Financial data

Cover Page

Cover Page	6 Months Ended
	Jun. 30, 2021
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	ERYTECH Pharma S.A.
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001624422
Current Fiscal Year End Date	--12-31

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Statement of Income (Loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Profit or loss [abstract]
Revenues	€ 0	€ 0
Other income	2,270	1,849
Operating income	2,270	1,849
Research and development	(23,209)	(28,846)
General and administrative	(8,027)	(8,372)
Operating expenses	(31,236)	(37,218)
Operating loss	(28,966)	(35,369)
Financial income	2,807	672
Financial expenses	(1,791)	(265)
Financial income (loss)	1,016	407
Income tax	(2)	0
Net loss	€ (27,952)	€ (34,962)
Basic / Diluted loss per share (€/share)	€ (1.22)	€ (1.95)

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Statement of Comprehensive Income (Loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Statement of comprehensive income [abstract]
Net loss	€ (27,952)	€ (34,962)
Elements that may be reclassified subsequently to income (loss)
Currency translation adjustment	(153)	(16)
Elements that may not be reclassified subsequently to income (loss)
Remeasurement of defined benefit liabilities	42	25
Tax effect	0	0
Other comprehensive income (loss)	(111)	9
Comprehensive income (loss)	€ (28,063)	€ (34,953)

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statement of Financial Position - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	€ 583	€ 589
Property, plant and equipment	19,818	20,862
Right of use	7,278	8,228
Other non-current assets	1,091	1,091
Total non-current assets	28,770	30,770
Current assets
Other current financial assets	516	59
Trade and other receivables	14	4
Other current assets	8,185	5,123
Cash and cash equivalents	46,323	44,446
Total current assets	55,038	49,632
TOTAL ASSETS	83,808	80,402
Shareholders’ equity
Share capital	2,644	2,006
Premiums related to share capital	86,209	120,705
Reserves	(26,130)	(24,616)
Translation reserve	1,591	1,744
Net loss for the period	(27,952)	(73,300)
Total shareholders’ equity	36,362	26,539
Non-current liabilities
Provisions - non-current portion	681	652
Financial liabilities – non-current portion	14,452	14,379
Derivative liabilities - non current portion	69	288
Lease liabilities - non-current portion	8,815	9,197
Total Non-current liabilities	24,017	24,516
Current liabilities
Financial liabilities – current portion	229	2,265
Derivative liabilities - current portion	3	129
Lease liabilities - current portion	1,732	1,607
Trade and other payables	17,639	20,910
Other current liabilities	3,826	4,436
Total current liabilities	23,429	29,347
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	€ 83,808	€ 80,402

Unaudited Interim Condensed C_4

Unaudited Interim Condensed Consolidated Statement of Cash Flow - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	€ (27,952)	€ (34,962)
Reconciliation of net loss and the cash used for operating activities
Gain or loss on exchange	(1,436)	(463)
Amortization and depreciation	2,494	2,509
Provision	71	(7)
Change in fair value of derivative liabilities	(750)	0
Expenses related to share-based payments	707	384
Gain or loss on disposal	0	(8)
Interest expense (income)	1,182	228
Income tax expense (income)	2	0
Operating cash flow before change in working capital	(25,682)	(32,319)
(Increase) decrease in inventories	0	(28)
(Increase) decrease in trade and other receivables	(10)	35
(Increase) decrease in other current assets	(2,686)	(162)
Increase (decrease) in trade and other payables	(3,639)	3,041
Increase (decrease) in other current liabilities	(594)	184
Change in working capital	(6,929)	3,070
Income tax paid	(2)	0
Net cash flow used in operating activities	(32,613)	(29,249)
Cash flows from investing activities
Acquisition of property, plant and equipment	(146)	(874)
Acquisition of intangible assets	0	(82)
Increase in non-current & current financial assets	(130)	(262)
Disposal of property, plant and equipment	0	86
Decrease in non-current & current financial assets	2	0
Net cash flow used in investing activities	(274)	(1,132)
Cash flows from financing activities
Capital increases, net of transaction costs	29,320	118
Subscription of warrants	0	12
Proceeds from borrowings, net of transaction costs	5,712	2,979
Repayment of borrowings	0	(62)
Allowance received from a lessor	0	194
Repayment of lease liability (IFRS 16)	(830)	(810)
Interests received (paid)	(146)	(175)
Net cash flow from (used in) financing activities	34,056	2,256
Exchange rate effect on cash in foreign currency	708	385
Increase (Decrease) in cash and cash equivalents	1,877	(27,740)
Net cash and cash equivalents at the beginning of the period	44,446	73,173
Net cash and cash equivalents at the closing of the period	€ 46,323	€ 45,433

Unaudited Interim Condensed C_5

Unaudited Interim Condensed Consolidated Statement of Changes in Shareholders' Equity - EUR (€) € in Thousands		Total	Share capital	Premiums related to the share capital	Reserves	Translation reserve	Net (income) loss
Beginning balance at Dec. 31, 2019		€ 85,560	€ 1,794	€ 281,688	€ (136,607)	€ 1,344	€ (62,659)
Net loss for the period		(34,962)					(34,962)
Other comprehensive income		9			25	(16)
Comprehensive income (loss)		(34,953)	0	0	25	(16)	(34,962)
Allocation of prior period loss		0		(54,208)	(8,451)		62,659
Allocation of reserves on premiums		0		(119,282)	119,282
Issue of ordinary shares		119	2	117
Share-based payment		384			384
Ending balance at Jun. 30, 2020		51,110	1,796	108,315	(25,367)	1,328	(34,962)
Beginning balance at Dec. 31, 2020		26,539	2,006	120,705	(24,616)	1,744	(73,300)
Net loss for the period		(27,952)					(27,952)
Other comprehensive income		(111)			42	(153)
Comprehensive income (loss)		(28,063)	0	0	42	(153)	(27,952)
Allocation of prior period loss		0		(71,037)	(2,263)		73,300
Issue of ordinary shares	[1]	39,834	638	39,196
Transaction costs	[2]	(2,655)		(2,655)
Share-based payment		707			707
Ending balance at Jun. 30, 2021		€ 36,362	€ 2,644	€ 86,209	€ (26,130)	€ 1,591	€ (27,952)
[1]	Includes €24,869 thousand related to the Registered Offering, €6,616 thousand to shares sold under the at-the-market (“ATM”) program (refer to note 4.5) and €8,350 thousand linked to the conversion of convertible notes (refer to note 4.6.1).
[2]	Includes €2,414 thousand related to the Registered Offering and €241 thousand to shares sold under the at-the-market (“ATM”) program.

Unaudited Interim Condensed C_6

Unaudited Interim Condensed Consolidated Statement of Changes in Shareholders' Equity (Parenthetical) € in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2021EUR (€)
Issue of ordinary shares	€ 39,834	[1]
Conversion of convertible notes	8,350
Share issue related cost	2,655	[2]
Registered Offering
Issue of ordinary shares	24,869
Share issue related cost	2,414
At-The-Market Offering
Issue of ordinary shares	6,616
Share issue related cost	€ 241
[1]	Includes €24,869 thousand related to the Registered Offering, €6,616 thousand to shares sold under the at-the-market (“ATM”) program (refer to note 4.5) and €8,350 thousand linked to the conversion of convertible notes (refer to note 4.6.1).
[2]	Includes €2,414 thousand related to the Registered Offering and €241 thousand to shares sold under the at-the-market (“ATM”) program.

Description of the Business

Description of the Business	6 Months Ended
	Jun. 30, 2021
Disclosure Of Description Of The Business [Abstract]
Description of the business	DESCRIPTION OF THE BUSINESS ERYTECH Pharma S.A. (“ ERYTECH ” and together with its subsidiary the “ Company ”) is incorporated in Lyon, France, and was founded in 2004 to develop and market innovative red blood cell-based therapeutics for cancer and orphan diseases. The Company’s most advanced product candidates is being developed for the treatment of pancreatic cancer. The Company completed its initial public offering on Euronext Paris in May 2013, raising €17.7 million, and on the Nasdaq Global Select Market in November 2017, raising €124.0 million ($144.0 million) on a gross basis before deducting offering expenses. The Company has incurred losses and negative cash flows from operations since its inception and had shareholders’ equity of €36,362 thousand as of June 30, 2021 as a result of several financing rounds, including an initial public offering. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates in development. The COVID-19 pandemic and the measures decided by the governments of the countries in which the Company operates have resulted in a delay of 3 to 4 months in patient enrollment in the TRYbeCA-1 trial and thus in the interim analysis. The end of recruitment and interim analysis occurred in January 2021 and February 2021, respectively. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. The situation on the financial markets and the delay in the TRYbeCA-1 trial due to the COVID-19 pandemic may impair the ability of the Company to raise capital when needed or on attractive terms in the future. The Company’s future operations are highly dependent on a combination of factors, including: (i) the success of its research and development (in particular the results of the TRYbeCA1 trial expected in the fourth quarter of 2021) ; (ii) regulatory approval and market acceptance of the Company’s proposed future products; (iii) the timely and successful completion of additional financing; and (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new debt or equity instruments. The accompanying unaudited interim condensed consolidated financial statements and related notes (the “ Unaudited Interim Condensed Consolidated Financial Statements ”) present the operations of ERYTECH Pharma S.A. and its subsidiary, ERYTECH Pharma, Inc. Major events of the first half of 2021 Business January 2021: • The Company announced the first patient enrolled in a Phase 1 investigator sponsored trial (IST), named rESPECT, of eryaspase for the first-line treatment of pancreatic cancer. The rESPECT Phase 1 IST will be conducted by Dr Marcus Noel (Associate Professor of Medicine at Georgetown University, Washington DC, USA). The trial will enroll patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. February 2021: • The Company announced that TRYbeCA-1, a Phase 3 clinical trial evaluating eryaspase in second-line pancreatic cancer, will continue without modification following a planned interim superiority analysis conducted by an Independent Data Monitoring Committee (IDMC). April 2021: • The Company announced the completion of enrollment of the first treatment cohort and the escalation to the next and potentially final dose level in the rESPECT Phase 1 IST. • The Company announced the initiation of the process of seeking marketing approval from the U.S. Food and Drug Administration for its lead product candidate eryaspase in patients with acute lymphoblastic leukemia (ALL) who developed hypersensitivity reactions to PEG-asparaginase based on the positive results of the NOPHO-sponsored Phase 2 clinical trial. Financing February 2021: • The Company sold 744,186 shares under the at-the-market (“ATM”) program, for gross proceeds of approximately €6.6 million ($8.0 million). March 2021: • As part of t he convertible notes’ agreement signed in June 2020, the Company issued a tranche of €3.0 million (60 OCABSA) on Mar ch 2, 2021. April 2021: • The Company announced a $30.0 million Registered Direct Offering. The Company entered into definitive agreements with several health-care focused institutional and accredited investors for the purchase and sale of 1,034,483 units (“Units”), each Unit consisting of four ordinary shares in the form of American Depositary Shares (each an “ADS”) and three warrants, each to purchase one ordinary share (each a “Warrant”), in a Registered Direct Offering. The subscription price for one Unit is $29.00 (€24.03), corresponding to $7.25 (€6.01) per ADS and associated 0.75 warrant. Each ADS represents the right to receive one ordinary share, €0.10 nominal value, of the Company. The Warrants have an exercise price of €7.50 ($9.05) per share, will be immediately exercisable upon issuance and will expire two years from the issuance date. The closing of the offering occurred on May 4, 2021. May 2021: • As part of t he convertible notes’ agreement signed in June 2020, the Company issued a tranche of €3.0 million (60 OCABSA) on May 19 , 2021.

Accounting Rules and Methods

Accounting Rules and Methods	6 Months Ended
	Jun. 30, 2021
Disclosure Of Accounting Rules And Methods [Abstract]
Accounting Rules and Methods	ACCOUNTING RULES AND METHODSBasis of preparation The Interim Condensed Consolidated Financial Statements have been prepared in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase. The Company has historically financed its growth by strengthening its equity in the form of capital increases and issuance of convertible bonds. At the approval date of the Unaudited Interim Condensed Consolidated Financial Statements, the Board of Directors believes that the Company will be able to fund its oper ations into the third quarter 2022, consideri ng: • Cash and cash equivalents held by the Company amounted to €46.3 million as of June 30, 2021. They are composed of cash and term deposits readily available without penalty; • The issuance of two tranches of convertibles notes of €3.0 million each in July 2021 and August 2021, as part of the financing agreement signed with Luxembourg-based European High Growth Opportunities Securitization Fund; • The possibility to use the OCABSA agreement allowing a potential fundraising up to a maximum of €33.0 million until June 2022, subject to the regulatory limit of 20% dilution and to authorizations of the general meeting, representing approximately €15.0 million based on the closing market price the day before the approval date of the Unaudited Interim Condensed Consolidated Financial Statements (€5.04). Considering the above factors and assumptions, the Company believes that it is able to fund its operations during the 12 months after the closing date. From this date, the Company will have to find additional funding. Various financing sources are considered among the issuance of new debt or equity instruments and partnership agreements. The Condensed Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standard Board (“ IASB ”) and were approved and authorized for issuance by the Board of Directors of the Company on September 16, 2021. Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the Unaudited Interim Condensed Consolidated Financial Statements of the Company are also prepared in accordance with IAS 34, Interim financial reporting , as adopted by the European Union (EU). As of June 30, 2021, all IFRS that the IASB had published and that are mandatory are the same as those adopted by the EU and mandatory in the EU. As a result, the Unaudited Interim Condensed Consolidated Financial Statements comply with International Financial Reporting Standards as published by the IASB and as adopted by the EU. As condensed financial statements, they do not include all information that would be required by the full IFRS standards. They must be read in conjunction with the consolidated financial statements for the year ended December 31, 2020. Except for the standards applicable as of January 1, 2021 described below, the standards applied in the preparation of the Condensed Consolidated Financial Statements are the same as those applied to prepare the financial statements as of December 31, 2020. The Company adopted the following standards, amendments and interpretations that are mandatory as of January 1, 2021: • Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 - Interest Rate Benchmark Reform – Phase 2 ; and • Amendment to IFRS 16 - Leases Covid 19-Related Rent Concessions These new texts did not have any significant impact on the Company’s results or financial position. The standards and interpretations that are optionally applicable to the Company as of June 30, 2021 were not applied in advance. Recently issued accounting pronouncements that may be relevant to the Company’s operations are as follows: • Amendments to IAS 1 - Classification of liabilities as current or non-current ; • Amendments to IAS 16 - Property, Plant and Equipment - Proceeds before intended use ; • Amendments to IAS 37 - Onerous contracts - cost of fulfilling a contrac t ; • Amendments to IAS 1 - Disclosure of Accounting policies ; • Amendments to IAS 8 - Definition of Accounting Estimates ; • Amendments to IFRS 16 - Leases Covid-19-Related Rent Concessions beyond 30 June 2021 ; • Amendments to IAS 12 - Deferred Tax related to Assets and Liabilities arising from a Single Transaction ; • Annual Improvements 2018-2020. Details of the Company’s subsidiary as of June 30, 2021 are as follows: Date of incorporation Percent of ownership interest Accounting method ERYTECH Pharma, Inc. April 2014 100% Consolidated There was no change in the scope of consolidation during the period. Functional Currency and Translation of Financial Statements into Presentation Currency The Unaudited Interim Condensed Consolidated Financial Statements are presented in euros, which is also the functional currency of the parent company, ERYTECH Pharma S.A. The exchange rates used for the translation of the financial statements of ERYTECH Pharma, Inc. are as follows: Exchange rate (USD per EUR) 06/30/2020 12/31/2020 06/30/2021 Weighted average rate 1.1015 1.1413 1.2057 Closing rate 1.1198 1.2271 1.1884 In accordance with IFRS 8 “ Operating Segments ”, reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Chief Executive Officer) to allocate resources and to assess performance. Information per operating segment The Company operates in a single operating segment: the conducting of research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases in order to market them in the future. Information per geographical segment Revenues from external customers (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) France 61 — United States 99 97 Total 160 97 July 2021: • The Company announced its intention to move forward towards the submission of a BLA to the US Food and Drug Administration (FDA) for eryaspase in hypersensitive acute lymphoblastic leukemia (ALL) patients following feedback from the agency in a pre-BLA meeting. • The U.S. Food and Drug Administration (FDA) granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). July / August 2021: • As part of t he convertible notes’ agreement signed in June 2020, the Company issued two tranches of €3.0 million (60 OCABSA) each on July 22 , 2021 and August 24, 2021, respectively.

Notes Related to the Unaudited

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
Notes related to the unaudited interim condensed consolidated statement of income (loss)	100% all the shares granted are acquired • If 0%NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS)Operating income The Company does not generate any revenue from the sale of its products considering its stage of development. (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Research Tax Credit 1,674 2,132 Subsidies 15 41 Revenues from licenses or other contracts 160 97 Total 1,849 2,270 During the first half of 2020, the Company received from BPI France a reimbursable advance of €2,979 thousand and a subsidy of €294 thousand under the TEDAC project, reducing the Research Tax Credit of €538 thousand. For the six months ended June 30, 2020 (amounts in thousands of euros) R&D Clinical studies Total Consumables 62 2,699 2,761 Rental and maintenance 53 597 650 Services, subcontracting and fees 457 14,713 15,170 Personnel expenses 1,356 6,787 8,143 Depreciation, amortization & provision 106 1,991 2,097 Other 8 17 25 Total 2,042 26,804 28,846 For the six months ended June 30, 2021 (amounts in thousands of euros) R&D Clinical studies Total Consumables 82 2,114 2,196 Rental and maintenance 77 675 752 Services, subcontracting and fees 312 9,581 9,893 Personnel expenses 1,045 7,134 8,179 Depreciation, amortization & provision 177 1,983 2,160 Other — 29 29 Total 1,693 21,516 23,209 The decrease in research and development expenses is mainly due to the decrease in external services, especially Contract Research Organization ("CRO") and hospital costs, linked to the completion of enrollment in the Phase 3 clinical trial for the treatment of pancreatic cancer (TRYbeCA-1) in January 2021. (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Consumables 89 94 Rental and maintenance 483 578 Services, subcontracting and fees 3,433 3,292 Personnel expenses 3,635 3,307 Depreciation and amortization 341 333 Other 391 423 Total 8,372 8,027 For the six months ended June 30, 2020 (amounts in thousands of euros) R&D Clinical studies Total Wages and salaries 962 5,033 5,995 Share-based payments (employees and executives) (38) 185 147 Social security expenses 432 1,569 2,001 Total personnel expenses 1,356 6,787 8,143 For the six months ended June 30, 2021 (amounts in thousands of euros) R&D Clinical studies Total Wages and salaries 700 5,256 5,956 Share-based payments (employees and executives) 55 295 350 Social security expenses 290 1,583 1,873 Total personnel expenses 1,045 7,134 8,179 The weighted average full-time employees (FTE) was 165 during the first half of 2020 and 155 during the first half of 2021. (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Wages and salaries 2,482 2,140 Share-based payments (employees and executive management) 179 311 Social security expenses 974 856 Total personnel expenses 3,635 3,307 The weighted average full-time employees (FTE) was 41 during the first half of 2020 and 41 during the first half of 2021. Share-based payments (IFRS 2 ) Stock-options (“SO”) plan The main assumptions used to determine the fair value of the plans granted during the first half of 2021 are: Grant in June 2021 Number of options 57,000 SO2020 Exercise price €4.78 Price of the underlying share €4.37 Expected dividends 0.00 % Volatility (1) 44.30 % Expected term 6 years 6.5 years Fair value of the plan (in thousands of euros) 96 (1) based on the historical volatility observed on the ERYP index on Euronext Free shares (“AGA”) plan The main assumptions used to determine the fair value of the plans granted during the first half of 2021 are: Grant in June 2021 Number of shares 50,831 AGA2020 Price of the underlying share €4.37 Expected dividends 0.00 % Volatility (1) 44.79 % Repo margin 5.00 % Maturity 5 years Performance criteria (2) ERYP € 4.78 Performance multiple ("PM") 2 Fair value of the plan (in thousands of euros) 121 (1) based on the historical volatility observed on the ERYP index on Euronext (2) performance criteria: progression of the quoted market share price between the grant date and the tranche acquisition date • Tri: (ERYPi - ERYP) / (ERYP x (PM – 1)) with ERYPi is equal to the maximum between the share price at the acquisition date and the average price of the 20-quoted market share price days before the grant date discounted by 5% • If TRi <=0% no shares granted are acquired • If Tri>100% all the shares granted are acquired • If 0%<TRi<100% shares granted are acquired following the TRi percentage Breakdown of expenses Plan name Amount in P&L in euros thousands as of June 30, 2020 of which employees of which executives of which directors AGA 167 120 47 — BSA 29 — — 29 SO 188 46 142 — Total 384 166 189 29 Plan name Amount in P&L in euros thousands as of June 30, 2021 of which employees of which executives of which directors AGA 308 161 146 — BSA 1 — — 1 SO 398 107 290 — Total 707 268 436 1 As of June 30, 2021 , the outstanding equity instruments could lead to the issuance of 2,220,859 potential shares. (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Income from short term deposits 3 11 Change in fair value of derivative liabilities (1) — 750 Other financial income 669 2,046 Financial income 672 2,807 Amortized cost of convertible notes (1) — (919) Financial expenses on lease liability (178) (156) Interest expense related to borrowings (54) (158) Other financial expenses (33) (558) Financial expenses (265) (1,791) Financial income (loss) 407 1,016 (1) Refer to note 4.6.1 Other income and expenses is mainly comprised of net foreign currency gains of €542 thousand during the first half of 2020 and €1,436 thousand during the first half of 2021. 06/30/2020 06/30/2021 (6 months) (6 months) Net loss (in thousands of euros) (34,962) (27,952) Weighted number of shares for the period (1) 17,942,117 22,842,857 Basic loss per share (€/share) (1.95) (1.22) Diluted loss per share (€/share) (1.95) (1.22) (1) after deduction of treasury shares (2,500 shares are held by the Company as treasury shares and recognized as a deduction of shareholders’ equity).

Notes Related to the Unaudite_2

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Detailed Information Of Financial Position [Abstract]
Notes related to the unaudited interim condensed consolidated statement of financial position	Financial liabilities (amounts in thousands of euros) Convertible notes Conditional advances Bank loans Other Total As of December 31, 2020 2,169 4,421 10,019 35 16,644 Collection 5,712 — — — 5,712 Fair value of embedded derivatives (404) — — — (404) Amortized cost 919 66 92 — 1,077 Conversion (8,350) — — — (8,350) Repayment — — — — — FX rate impact — — — 2 2 As of June 30, 2021 46 4,487 10,111 37 14,681 Financial liabilities by maturity June 30, 2021 (in thousands of euros) Less than one year One to three years Three to five years More than five years Total Convertible notes 46 — — — 46 Conditional advances — — — 4,487 4,487 Bank loans 182 3,526 5,099 1,304 10,111 Other — 37 — — 37 Total financial liabilities 228 3,563 5,099 5,791 14,681 (in thousands of euros) Lease liabilities As of December 31, 2020 10,804 Increase without cash impact 379 Repayment (830) Decrease without cash impact — FX rate impact 194 Capitalized interests — As of June 30, 2021 10,547 Lease liabilities by maturity Less than one year One to three years Three to five years More than five years Total As of June 30, 2021 1,732 2,965 2,276 3,574 10,547 (amounts in thousands of euros) 12/31/2020 06/30/2021 Vendors 4,706 3,352 Vendors - accruals 16,204 14,287 Total trade and other payables 20,910 17,639 Social liabilities, taxation and social security 4,149 3,604 Fixed assets payables 86 33 Deferred revenue 148 120 Other payables 53 69 Total other current liabilities 4,436 3,826 Hospital costs accruals amounted to €10,770 thousand as of December 31, 2020 and €10,557 thousand as of June 30, 2021. As of December 31, 2020 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current assets 1,091 1,091 1,091 Other current financial assets 59 59 59 Trade and other receivables 4 4 4 Other current assets 4,330 4,330 4,330 Cash and cash equivalents (2) 44,446 44,446 44,446 Total financial assets 49,930 44,446 — 5,484 — 49,930 Financial liabilities - non current portion (3) 14,379 14,379 14,379 Derivative liabilities - non current portion (5) 288 288 288 Lease liabilities - non current portion (4) 9,197 9,197 9,197 Financial liabilities - current portion (3) 2,265 2,265 2,265 Derivative liabilities - current portion (5) 129 129 129 Lease liabilities - current portion (4) 1,607 1,607 1,607 Trade and other payables 20,910 20,910 20,910 Other current liabilities 4,288 4,288 4,288 Total financial liabilities 53,063 417 — — 52,646 53,063 As of June 30, 2021 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current assets 1,091 1,091 1,091 Other current financial assets 516 516 516 Trade and other receivables 14 14 14 Other current assets 6,669 6,669 6,669 Cash and cash equivalents (2) 46,323 46,323 46,323 Total financial assets 54,613 46,323 — 8,290 — 54,613 Financial liabilities - non current portion (3) 14,452 14,452 14,452 Derivative liabilities - non current portion (5) 69 69 69 Lease liabilities - non current portion (4) 8,815 8,815 8,815 Financial liabilities - current portion (3) 229 229 229 Derivative liabilities - current portion (5) 3 3 3 Lease liabilities - current portion (4) 1,732 1,732 1,732 Trade and other payables 17,639 17,639 17,639 Other current liabilities 3,706 3,706 3,706 Total financial liabilities 46,645 72 — — 46,573 46,645 (1) The carrying amount of these assets and liabilities is a reasonable approximation of their fair value. (2) Cash and cash equivalents are comprised of cash in bank and term deposit accounts, which are measured using level 1 measurements. (3) The fair value of financial liabilities is determined using level 2 measurements. (4) The fair value of lease liabilities is determined using level 2 measurements. (5) The fair value of derivative liabilities is determined using level 3 measurements.	NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITIONProperty, plant and equipment (amounts in thousands of euros) General equipment, fixtures and fittings Plant, equipment and tooling Office equipment and computers Assets under construction Advance payment TOTAL GROSS VALUE As of December 31, 2020 20,701 5,787 1,204 77 — 27,769 Increase 25 — 16 42 11 94 Decrease — — (9) — — (9) FX rate impact 580 91 13 — — 684 Reclassification — — 64 (53) 11 22 As of June 30, 2021 21,306 5,878 1,288 66 22 28,560 ACCUMULATED DEPRECIATION As of December 31, 2020 (4,127) (2,092) (688) — — (6,907) Increase (1,066) (535) (110) — — (1,711) Decrease — — 9 — — 9 FX rate impact (102) (25) (6) — — (133) Reclassification — — — — — — As of June 30, 2021 (5,295) (2,652) (795) — — (8,742) NET VALUE As of December 31, 2020 16,574 3,695 516 77 — 20,862 As of June 30, 2021 16,011 3,226 493 66 22 19,818 (amounts in thousands of euros) Buildings Plant, equipment and tooling Transport equipment Office equipment and computers TOTAL GROSS VALUE As of December 31, 2020 10,846 954 73 118 11,991 Increase — 376 3 — 379 Decrease (1,715) — — — (1,715) FX rate impact 145 5 — — 150 Reclassification — — — — — As of June 30, 2021 9,276 1,335 76 118 10,805 ACCUMULATED DEPRECIATION As of December 31, 2020 (2,649) (954) (42) (118) (3,763) Increase (726) (37) (12) — (775) Decrease 1,050 — — — 1,050 FX rate impact (38) (1) — — (39) Reclassification — — — — — As of June 30, 2021 (2,363) (992) (54) (118) (3,527) NET VALUE As of December 31, 2020 8,197 — 31 — 8,228 As of June 30, 2021 6,913 343 22 — 7,278 The decrease is linked to the sublease of our premises in Cambridge, United States. (amounts in thousands of euros) 12/31/2020 06/30/2021 Trade and other receivables 4 14 Total trade and other receivables 4 14 Research Tax Credit 3,432 5,564 Other receivables (including tax and social receivables) 898 660 Net investment in a sublease — 446 Prepaid expenses 793 1,515 Total other current assets 5,123 8,185 Research Tax Credit (Crédit d’Impôt Recherche or “CIR”) As of June 30, 2021, the CIR receivable included the Research Tax Credit for the 2020 financial year and the CIR estimate for the first half of 2021. Prepaid expenses Prepaid expenses mainly related to advance payments for directors and officers' insurance ( €1,026 thousand ). (amounts in thousands of euros) 12/31/2020 06/30/2021 Current account 34,348 41,221 Term deposits 10,098 5,102 Total cash and cash equivalents as reported in statement of financial position 44,446 46,323 Bank overdrafts — — Total cash and cash equivalents as reported in statement of cash flow 44,446 46,323 As of December 31, 2020, term deposits included a term deposit of €10.0 million with a maturity of one month and deposits of €0.1 million convertible into cash immediately. As of June 30, 2021, term deposits included a term deposit of €5.0 million with a maturity of one month and deposits of €0.1 million convertible into cash immediately. As of June 30, 2021, the capital of the Company consisted of 26,438,955 shares, fully paid up, with a nominal value of 0.10 euro. Number of shares As of December 31, 2020 20,057,562 Shares issued as part of the Registered Offering 4,137,932 Shares sold under the at-the-market (“ATM”) program 744,186 Conversion of convertible notes ("OCA") 1,493,320 Free shares acquired 5,955 As of June 30, 2021 26,438,955 In February 2021, t he Company sold 744,186 shares under the at-the-market (“ATM”) program, for gross proceeds of €6.6 million (net proceeds of approximately €6.4 million). In April 2021, the Company issued 4,137,932 shares as part of the Registered Offering, for gross proceeds of €24.9 million (net proceeds of approximately €22.5 million). During the first half of 2021, t he transaction costs amounted to €2.7 million (of which €2.4 million related to the Registered Offering and €0.2 million to shares sold under the at-the-market (“ATM”) program) and relates to bank fees, legal counsels, advisors and auditors’ fees. The Company issued 2 tranches of €3.0 million each on March 2, 2021 and May 19, 2021, respectively. During the first half of 2021, 167 OCA were converted into 1,493,320 shares. As of June 30, 2021, 1 OCA and 235,690 BSA are outstanding. The average effective interest rate of the tranches issued during the first half of 2021 was 13.0%. Fair value of the conversion option is estimated with a Monte-Carlo valuation model using the following main assumptions: 12/31/2020 At the issuance date 06/30/2021 Tranche 6 Tranche 7 Number of convertible notes 48 60 60 1 Estimated conversion price € 6.75 € 6.94 € 4.87 € 3.73 Expected term 1 month 1 month 1 month 1 day Fair value (in thousands of euros) 129 160 160 3 Fair value of the warrants is estimated with a Black & Scholes valuation model using the following main assumptions: 12/31/2020 At the issuance date 06/30/2021 Tranche 6 Tranche 7 Number of warrants 168,350 33,670 33,670 235,690 Price of the underlying share € 7.11 € 7.30 € 5.13 € 3.93 Expected dividends — % — % — % — % Volatility 58.11 % 58.40 % 62.24 % 61.13 % Expected term 2 years 1 year, 10 months 1 year, 7 months 1 year, 6 months Fair value (in thousands of euros) 288 59 25 69 Sensitivity analysis as of June 30, 2021 A change in the main assumptions used for the valuation of the conversion option would have no significant impact in the fair value . A change in the following assumptions used for the valuation of the warrants could change the fair value as follows. (in thousands of euros) Price of the underlying share Volatility -10% 3.93 +10% - 10 percentage points 25 38 54 61% 49 69 93 +10 percentage points 80 107 137

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2021
Disclosure of transactions between related parties [abstract]
Related parties	RELATED PARTIES The Company’s related parties include the Chairman of the Board of Directors (Jean-Paul Kress), the Chief Executive Officer (Gil Beyen), the two Deputy General Managers (Jérôme Bailly and Eric Soyer), members of the Board of Directors and members of the executive committee. The remuneration of directors and other members of the executive committee was as set forth in the table below . 06/30/2020 06/30/2021 (amounts in thousands of euros) Salary / fees Retirement benefits Share based payments Salary / fees Retirement benefits Share based payments Executive officers / VP and qualified person 639 11 171 593 11 254 Executive committee 593 11 19 764 12 183 Board of directors 147 0 29 153 — 1 Total 1,379 22 219 1,510 23 438 The Company has no other related parties.

Off-Balance Sheet Commitments

Off-Balance Sheet Commitments	6 Months Ended
	Jun. 30, 2021
Disclosure Of Off-Balance Sheet Commitments [Abstract]
Off-balance sheet commitments	OFF-BALANCE SHEET COMMITMENTS The off-balance-sheet commitments as of December 31, 2020 have not changed significantly during the first half of 2021, except for the following commitments: Sublease in the United-States In May 2021, the Company signed a sublease agreement for a portion of its premises located in Cambridge. As part of this agreement, the Company received a security deposit in the form of a letter of credit in the amount of $59 thousand.

Accounting Rules and Methods (P

Accounting Rules and Methods (Policies)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Accounting Rules And Methods [Abstract]
Basis of preparation	Basis of preparation The Interim Condensed Consolidated Financial Statements have been prepared in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase. The Company has historically financed its growth by strengthening its equity in the form of capital increases and issuance of convertible bonds. At the approval date of the Unaudited Interim Condensed Consolidated Financial Statements, the Board of Directors believes that the Company will be able to fund its oper ations into the third quarter 2022, consideri ng: • Cash and cash equivalents held by the Company amounted to €46.3 million as of June 30, 2021. They are composed of cash and term deposits readily available without penalty; • The issuance of two tranches of convertibles notes of €3.0 million each in July 2021 and August 2021, as part of the financing agreement signed with Luxembourg-based European High Growth Opportunities Securitization Fund; • The possibility to use the OCABSA agreement allowing a potential fundraising up to a maximum of €33.0 million until June 2022, subject to the regulatory limit of 20% dilution and to authorizations of the general meeting, representing approximately €15.0 million based on the closing market price the day before the approval date of the Unaudited Interim Condensed Consolidated Financial Statements (€5.04). Considering the above factors and assumptions, the Company believes that it is able to fund its operations during the 12 months after the closing date. From this date, the Company will have to find additional funding. Various financing sources are considered among the issuance of new debt or equity instruments and partnership agreements.
Statement of compliance	Statement of compliance The Condensed Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standard Board (“ IASB ”) and were approved and authorized for issuance by the Board of Directors of the Company on September 16, 2021. Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the Unaudited Interim Condensed Consolidated Financial Statements of the Company are also prepared in accordance with IAS 34, Interim financial reporting , as adopted by the European Union (EU). As of June 30, 2021, all IFRS that the IASB had published and that are mandatory are the same as those adopted by the EU and mandatory in the EU. As a result, the Unaudited Interim Condensed Consolidated Financial Statements comply with International Financial Reporting Standards as published by the IASB and as adopted by the EU. As condensed financial statements, they do not include all information that would be required by the full IFRS standards. They must be read in conjunction with the consolidated financial statements for the year ended December 31, 2020. Except for the standards applicable as of January 1, 2021 described below, the standards applied in the preparation of the Condensed Consolidated Financial Statements are the same as those applied to prepare the financial statements as of December 31, 2020. The Company adopted the following standards, amendments and interpretations that are mandatory as of January 1, 2021: • Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 - Interest Rate Benchmark Reform – Phase 2 ; and • Amendment to IFRS 16 - Leases Covid 19-Related Rent Concessions These new texts did not have any significant impact on the Company’s results or financial position. The standards and interpretations that are optionally applicable to the Company as of June 30, 2021 were not applied in advance. Recently issued accounting pronouncements that may be relevant to the Company’s operations are as follows: • Amendments to IAS 1 - Classification of liabilities as current or non-current ; • Amendments to IAS 16 - Property, Plant and Equipment - Proceeds before intended use ; • Amendments to IAS 37 - Onerous contracts - cost of fulfilling a contrac t ; • Amendments to IAS 1 - Disclosure of Accounting policies ; • Amendments to IAS 8 - Definition of Accounting Estimates ; • Amendments to IFRS 16 - Leases Covid-19-Related Rent Concessions beyond 30 June 2021 ; • Amendments to IAS 12 - Deferred Tax related to Assets and Liabilities arising from a Single Transaction ; • Annual Improvements 2018-2020.
Scope of consolidation	Scope of consolidation Details of the Company’s subsidiary as of June 30, 2021 are as follows: Date of incorporation Percent of ownership interest Accounting method ERYTECH Pharma, Inc. April 2014 100% Consolidated There was no change in the scope of consolidation during the period.
Foreign currencies	Foreign currencies Functional Currency and Translation of Financial Statements into Presentation Currency The Unaudited Interim Condensed Consolidated Financial Statements are presented in euros, which is also the functional currency of the parent company, ERYTECH Pharma S.A. The exchange rates used for the translation of the financial statements of ERYTECH Pharma, Inc. are as follows: Exchange rate (USD per EUR) 06/30/2020 12/31/2020 06/30/2021 Weighted average rate 1.1015 1.1413 1.2057 Closing rate 1.1198 1.2271 1.1884
Use of estimates and judgements	Use of estimates and judgments The preparation of the Unaudited Interim Condensed Consolidated Financial Statements in accordance with the rules prescribed by the IFRS requires the use of estimates and the formulation of assumptions having an impact on the financial statements. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The main areas of estimates are described in the annual consolidated financial statements.
Presentation of the statement of income (loss)	Presentation of the statement of income (loss) The Company presents its statement of income (loss) by function. As of today, the main activity of the Company is research and development. Consequently, only research and development expenses and general administrative expenses functions are considered to be representative of the Company's activity. This distinction reflects the analytical assignment of the personnel, external expenses and depreciation and amortization. The detail of the expenses by nature is disclosed in note 3.2.
Segment reporting	Segment reporting In accordance with IFRS 8 “ Operating Segments ”, reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Chief Executive Officer) to allocate resources and to assess performance. Information per operating segment The Company operates in a single operating segment: the conducting of research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases in order to market them in the future. Information per geographical segment Revenues from external customers (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) France 61 — United States 99 97 Total 160 97
Events after the close of the reporting period	Events after the close of the reporting period July 2021: • The Company announced its intention to move forward towards the submission of a BLA to the US Food and Drug Administration (FDA) for eryaspase in hypersensitive acute lymphoblastic leukemia (ALL) patients following feedback from the agency in a pre-BLA meeting. • The U.S. Food and Drug Administration (FDA) granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). July / August 2021: • As part of t he convertible notes’ agreement signed in June 2020, the Company issued two tranches of €3.0 million (60 OCABSA) each on July 22 , 2021 and August 24, 2021, respectively.

Accounting Rules and Methods (T

Accounting Rules and Methods (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Accounting Rules And Methods [Abstract]
Summary of Details of the Company's Subsidiary	Details of the Company’s subsidiary as of June 30, 2021 are as follows: Date of incorporation Percent of ownership interest Accounting method ERYTECH Pharma, Inc. April 2014 100% Consolidated There was no change in the scope of consolidation during the period.
Summary of Accounting Policy for Exchange Rates	The exchange rates used for the translation of the financial statements of ERYTECH Pharma, Inc. are as follows: Exchange rate (USD per EUR) 06/30/2020 12/31/2020 06/30/2021 Weighted average rate 1.1015 1.1413 1.2057 Closing rate 1.1198 1.2271 1.1884
Summary of Geographical Segment Information	Information per geographical segment Revenues from external customers (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) France 61 — United States 99 97 Total 160 97

Notes Related to the Unaudite_3

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
Summary of Detailed Information of Operating Income	The Company does not generate any revenue from the sale of its products considering its stage of development. (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Research Tax Credit 1,674 2,132 Subsidies 15 41 Revenues from licenses or other contracts 160 97 Total 1,849 2,270
Summary of Operating Expense by Nature	Research and development expenses For the six months ended June 30, 2020 (amounts in thousands of euros) R&D Clinical studies Total Consumables 62 2,699 2,761 Rental and maintenance 53 597 650 Services, subcontracting and fees 457 14,713 15,170 Personnel expenses 1,356 6,787 8,143 Depreciation, amortization & provision 106 1,991 2,097 Other 8 17 25 Total 2,042 26,804 28,846 For the six months ended June 30, 2021 (amounts in thousands of euros) R&D Clinical studies Total Consumables 82 2,114 2,196 Rental and maintenance 77 675 752 Services, subcontracting and fees 312 9,581 9,893 Personnel expenses 1,045 7,134 8,179 Depreciation, amortization & provision 177 1,983 2,160 Other — 29 29 Total 1,693 21,516 23,209 (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Consumables 89 94 Rental and maintenance 483 578 Services, subcontracting and fees 3,433 3,292 Personnel expenses 3,635 3,307 Depreciation and amortization 341 333 Other 391 423 Total 8,372 8,027
Summary of Personal Expenses	Research and development expenses For the six months ended June 30, 2020 (amounts in thousands of euros) R&D Clinical studies Total Wages and salaries 962 5,033 5,995 Share-based payments (employees and executives) (38) 185 147 Social security expenses 432 1,569 2,001 Total personnel expenses 1,356 6,787 8,143 For the six months ended June 30, 2021 (amounts in thousands of euros) R&D Clinical studies Total Wages and salaries 700 5,256 5,956 Share-based payments (employees and executives) 55 295 350 Social security expenses 290 1,583 1,873 Total personnel expenses 1,045 7,134 8,179 (amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Wages and salaries 2,482 2,140 Share-based payments (employees and executive management) 179 311 Social security expenses 974 856 Total personnel expenses 3,635 3,307
Summary of Assumptions Used to Determine Fair Value of Plans Granted	The main assumptions used to determine the fair value of the plans granted during the first half of 2021 are: Grant in June 2021 Number of options 57,000 SO2020 Exercise price €4.78 Price of the underlying share €4.37 Expected dividends 0.00 % Volatility (1) 44.30 % Expected term 6 years 6.5 years Fair value of the plan (in thousands of euros) 96 (1) based on the historical volatility observed on the ERYP index on Euronext
Summary of Assumptions Used Determine Fair Value of Free Shares Plans Granted	100% all the shares granted are acquired " id="sjs-B8" xml:space="preserve">The main assumptions used to determine the fair value of the plans granted during the first half of 2021 are: Grant in June 2021 Number of shares 50,831 AGA2020 Price of the underlying share €4.37 Expected dividends 0.00 % Volatility (1) 44.79 % Repo margin 5.00 % Maturity 5 years Performance criteria (2) ERYP € 4.78 Performance multiple ("PM") 2 Fair value of the plan (in thousands of euros) 121 (1) based on the historical volatility observed on the ERYP index on Euronext (2) performance criteria: progression of the quoted market share price between the grant date and the tranche acquisition date • Tri: (ERYPi - ERYP) / (ERYP x (PM – 1)) with ERYPi is equal to the maximum between the share price at the acquisition date and the average price of the 20-quoted market share price days before the grant date discounted by 5% • If TRi <=0% no shares granted are acquired • If Tri>100% all the shares granted are acquired
Breakdown of Expenses of Plans per Financial Year	Breakdown of expenses Plan name Amount in P&L in euros thousands as of June 30, 2020 of which employees of which executives of which directors AGA 167 120 47 — BSA 29 — — 29 SO 188 46 142 — Total 384 166 189 29 Plan name Amount in P&L in euros thousands as of June 30, 2021 of which employees of which executives of which directors AGA 308 161 146 — BSA 1 — — 1 SO 398 107 290 — Total 707 268 436 1
Summary of Financial income (loss)	(amounts in thousands of euros) 06/30/2020 06/30/2021 (6 months) (6 months) Income from short term deposits 3 11 Change in fair value of derivative liabilities (1) — 750 Other financial income 669 2,046 Financial income 672 2,807 Amortized cost of convertible notes (1) — (919) Financial expenses on lease liability (178) (156) Interest expense related to borrowings (54) (158) Other financial expenses (33) (558) Financial expenses (265) (1,791) Financial income (loss) 407 1,016 (1) Refer to note 4.6.1
Summary of Basic Earnings per Share and Diluted Earnings (Loss) per Share	06/30/2020 06/30/2021 (6 months) (6 months) Net loss (in thousands of euros) (34,962) (27,952) Weighted number of shares for the period (1) 17,942,117 22,842,857 Basic loss per share (€/share) (1.95) (1.22) Diluted loss per share (€/share) (1.95) (1.22) (1) after deduction of treasury shares (2,500 shares are held by the Company as treasury shares and recognized as a deduction of shareholders’ equity).

Notes Related to the Unaudite_4

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Detailed Information Of Financial Position [Abstract]
Schedule of Property, Plant and Equipment	(amounts in thousands of euros) General equipment, fixtures and fittings Plant, equipment and tooling Office equipment and computers Assets under construction Advance payment TOTAL GROSS VALUE As of December 31, 2020 20,701 5,787 1,204 77 — 27,769 Increase 25 — 16 42 11 94 Decrease — — (9) — — (9) FX rate impact 580 91 13 — — 684 Reclassification — — 64 (53) 11 22 As of June 30, 2021 21,306 5,878 1,288 66 22 28,560 ACCUMULATED DEPRECIATION As of December 31, 2020 (4,127) (2,092) (688) — — (6,907) Increase (1,066) (535) (110) — — (1,711) Decrease — — 9 — — 9 FX rate impact (102) (25) (6) — — (133) Reclassification — — — — — — As of June 30, 2021 (5,295) (2,652) (795) — — (8,742) NET VALUE As of December 31, 2020 16,574 3,695 516 77 — 20,862 As of June 30, 2021 16,011 3,226 493 66 22 19,818
Schedule of Right of Use	(amounts in thousands of euros) Buildings Plant, equipment and tooling Transport equipment Office equipment and computers TOTAL GROSS VALUE As of December 31, 2020 10,846 954 73 118 11,991 Increase — 376 3 — 379 Decrease (1,715) — — — (1,715) FX rate impact 145 5 — — 150 Reclassification — — — — — As of June 30, 2021 9,276 1,335 76 118 10,805 ACCUMULATED DEPRECIATION As of December 31, 2020 (2,649) (954) (42) (118) (3,763) Increase (726) (37) (12) — (775) Decrease 1,050 — — — 1,050 FX rate impact (38) (1) — — (39) Reclassification — — — — — As of June 30, 2021 (2,363) (992) (54) (118) (3,527) NET VALUE As of December 31, 2020 8,197 — 31 — 8,228 As of June 30, 2021 6,913 343 22 — 7,278
Schedule of Trade Receivables and Other Current Assets	(amounts in thousands of euros) 12/31/2020 06/30/2021 Trade and other receivables 4 14 Total trade and other receivables 4 14 Research Tax Credit 3,432 5,564 Other receivables (including tax and social receivables) 898 660 Net investment in a sublease — 446 Prepaid expenses 793 1,515 Total other current assets 5,123 8,185
Summary of Cash and Cash Equivalents	(amounts in thousands of euros) 12/31/2020 06/30/2021 Current account 34,348 41,221 Term deposits 10,098 5,102 Total cash and cash equivalents as reported in statement of financial position 44,446 46,323 Bank overdrafts — — Total cash and cash equivalents as reported in statement of cash flow 44,446 46,323
Summary of Common Shares	Number of shares As of December 31, 2020 20,057,562 Shares issued as part of the Registered Offering 4,137,932 Shares sold under the at-the-market (“ATM”) program 744,186 Conversion of convertible notes ("OCA") 1,493,320 Free shares acquired 5,955 As of June 30, 2021 26,438,955
Summary of Financial Liabilities by Type	(amounts in thousands of euros) Convertible notes Conditional advances Bank loans Other Total As of December 31, 2020 2,169 4,421 10,019 35 16,644 Collection 5,712 — — — 5,712 Fair value of embedded derivatives (404) — — — (404) Amortized cost 919 66 92 — 1,077 Conversion (8,350) — — — (8,350) Repayment — — — — — FX rate impact — — — 2 2 As of June 30, 2021 46 4,487 10,111 37 14,681
Summary of Financial Liabilities by Maturity	Financial liabilities by maturity June 30, 2021 (in thousands of euros) Less than one year One to three years Three to five years More than five years Total Convertible notes 46 — — — 46 Conditional advances — — — 4,487 4,487 Bank loans 182 3,526 5,099 1,304 10,111 Other — 37 — — 37 Total financial liabilities 228 3,563 5,099 5,791 14,681
Summary of Derivative Financial Instruments	Fair value of the conversion option is estimated with a Monte-Carlo valuation model using the following main assumptions: 12/31/2020 At the issuance date 06/30/2021 Tranche 6 Tranche 7 Number of convertible notes 48 60 60 1 Estimated conversion price € 6.75 € 6.94 € 4.87 € 3.73 Expected term 1 month 1 month 1 month 1 day Fair value (in thousands of euros) 129 160 160 3 Fair value of the warrants is estimated with a Black & Scholes valuation model using the following main assumptions: 12/31/2020 At the issuance date 06/30/2021 Tranche 6 Tranche 7 Number of warrants 168,350 33,670 33,670 235,690 Price of the underlying share € 7.11 € 7.30 € 5.13 € 3.93 Expected dividends — % — % — % — % Volatility 58.11 % 58.40 % 62.24 % 61.13 % Expected term 2 years 1 year, 10 months 1 year, 7 months 1 year, 6 months Fair value (in thousands of euros) 288 59 25 69
Sensitivity Analysis For The Valuation Of Warrants	A change in the following assumptions used for the valuation of the warrants could change the fair value as follows. (in thousands of euros) Price of the underlying share Volatility -10% 3.93 +10% - 10 percentage points 25 38 54 61% 49 69 93 +10 percentage points 80 107 137
Summary of Lease Liabilities	(in thousands of euros) Lease liabilities As of December 31, 2020 10,804 Increase without cash impact 379 Repayment (830) Decrease without cash impact — FX rate impact 194 Capitalized interests — As of June 30, 2021 10,547
Summary of Lease Liabilities by Maturity	Lease liabilities by maturity Less than one year One to three years Three to five years More than five years Total As of June 30, 2021 1,732 2,965 2,276 3,574 10,547
Summary of Trade Payables and Other Current Liabilities	(amounts in thousands of euros) 12/31/2020 06/30/2021 Vendors 4,706 3,352 Vendors - accruals 16,204 14,287 Total trade and other payables 20,910 17,639 Social liabilities, taxation and social security 4,149 3,604 Fixed assets payables 86 33 Deferred revenue 148 120 Other payables 53 69 Total other current liabilities 4,436 3,826
Summary of Financial Instruments Recognized in the Consolidated Statement of Financial Position	As of December 31, 2020 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current assets 1,091 1,091 1,091 Other current financial assets 59 59 59 Trade and other receivables 4 4 4 Other current assets 4,330 4,330 4,330 Cash and cash equivalents (2) 44,446 44,446 44,446 Total financial assets 49,930 44,446 — 5,484 — 49,930 Financial liabilities - non current portion (3) 14,379 14,379 14,379 Derivative liabilities - non current portion (5) 288 288 288 Lease liabilities - non current portion (4) 9,197 9,197 9,197 Financial liabilities - current portion (3) 2,265 2,265 2,265 Derivative liabilities - current portion (5) 129 129 129 Lease liabilities - current portion (4) 1,607 1,607 1,607 Trade and other payables 20,910 20,910 20,910 Other current liabilities 4,288 4,288 4,288 Total financial liabilities 53,063 417 — — 52,646 53,063 As of June 30, 2021 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current assets 1,091 1,091 1,091 Other current financial assets 516 516 516 Trade and other receivables 14 14 14 Other current assets 6,669 6,669 6,669 Cash and cash equivalents (2) 46,323 46,323 46,323 Total financial assets 54,613 46,323 — 8,290 — 54,613 Financial liabilities - non current portion (3) 14,452 14,452 14,452 Derivative liabilities - non current portion (5) 69 69 69 Lease liabilities - non current portion (4) 8,815 8,815 8,815 Financial liabilities - current portion (3) 229 229 229 Derivative liabilities - current portion (5) 3 3 3 Lease liabilities - current portion (4) 1,732 1,732 1,732 Trade and other payables 17,639 17,639 17,639 Other current liabilities 3,706 3,706 3,706 Total financial liabilities 46,645 72 — — 46,573 46,645 (1) The carrying amount of these assets and liabilities is a reasonable approximation of their fair value. (2) Cash and cash equivalents are comprised of cash in bank and term deposit accounts, which are measured using level 1 measurements. (3) The fair value of financial liabilities is determined using level 2 measurements. (4) The fair value of lease liabilities is determined using level 2 measurements. (5) The fair value of derivative liabilities is determined using level 3 measurements.

Related Parties (Tables)

Related Parties (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure of transactions between related parties [abstract]
Summary of remuneration of directors and members of the executive committee	The remuneration of directors and other members of the executive committee was as set forth in the table below . 06/30/2020 06/30/2021 (amounts in thousands of euros) Salary / fees Retirement benefits Share based payments Salary / fees Retirement benefits Share based payments Executive officers / VP and qualified person 639 11 171 593 11 254 Executive committee 593 11 19 764 12 183 Board of directors 147 0 29 153 — 1 Total 1,379 22 219 1,510 23 438

Description of the Business (De

Description of the Business (Detail) € / shares in Units, $ / shares in Units, € in Thousands, $ in Millions	1 Months Ended							6 Months Ended
	Apr. 30, 2021USD ($)$ / sharesshares	Apr. 30, 2021€ / shares	Feb. 28, 2021EUR (€)shares	Feb. 28, 2021USD ($)shares	Nov. 30, 2017EUR (€)	Nov. 30, 2017USD ($)	May 31, 2013EUR (€)	Jun. 30, 2021EUR (€)€ / sharesshares		Jun. 30, 2020EUR (€)	May 19, 2021EUR (€)shares	Mar. 02, 2021EUR (€)shares	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)
Disclosure Of Description Of Business [Line Items]
Initial public offering amount					€ 124,000	$ 144	€ 17,700
Shareholders' equity | €								€ 36,362		€ 51,110			€ 26,539	€ 85,560
Issue of ordinary shares | €								39,834	[1]	€ 119
Convertible notes | €								€ 46			€ 3,000	€ 3,000
Nominal value (in euro per share) | € / shares								€ 0.10
At-The-Market Offering
Disclosure Of Description Of Business [Line Items]
Number of shares issued during the period			744,186	744,186				744,186
Issue of ordinary shares			€ 6,600	$ 8				€ 6,616
Registered Direct Offering
Disclosure Of Description Of Business [Line Items]
Issue of ordinary shares | $	$ 30
Number of units issued	1,034,483
Number of ordinary shares issued, per unit (in shares)	4
Number of warrants issued, per unit (in shares)	3
Number of shares purchased per warrant (in shares)	1
Subscription price per unit (in dollar per share) | (per share)	$ 29	€ 24.03
Subscription price per unit (in euro per share) | (per share)	29	24.03
Subscription price per ADS, for one unit (in dollar per share) | (per share)	7.25	6.01
Subscription price per ADS, for one unit (in euro per share) | (per share)	$ 7.25	6.01
Associated warrant per unit (in shares)	0.75
Number of shares received per ADS (in shares)	1
Nominal value (in euro per share) | € / shares		0.10
Exercise price of share subscription warrants (in euro per share) | (per share)	$ 9.05	7.50
Exercise price of share subscription warrants (in dollar per share) | (per share)	$ 9.05	€ 7.50
Share subscription warrants term	2 years
Derivatives
Disclosure Of Description Of Business [Line Items]
Number of convertible notes issued (in shares)											60	60
TRYBECA Trial One | Bottom of range
Disclosure Of Description Of Business [Line Items]
Duration of delay in patient enrollment								3 months
TRYBECA Trial One | Top of range
Disclosure Of Description Of Business [Line Items]
Duration of delay in patient enrollment								4 months
[1]	Includes €24,869 thousand related to the Registered Offering, €6,616 thousand to shares sold under the at-the-market (“ATM”) program (refer to note 4.5) and €8,350 thousand linked to the conversion of convertible notes (refer to note 4.6.1).

Accounting Rules and Methods -

Accounting Rules and Methods - Additional Information (Details) € / shares in Units, € in Thousands	1 Months Ended	3 Months Ended
	Aug. 24, 2021EUR (€)tranchshares	May 19, 2021EUR (€)tranchshares	Jul. 22, 2021EUR (€)shares	Jun. 30, 2021EUR (€)€ / shares	Mar. 02, 2021EUR (€)shares	Dec. 31, 2020EUR (€)
Disclosure Of Significant Accounting Policies [Line Items]
Cash and cash equivalents				€ 46,323		€ 44,446
Number of tranches of convertible notes issued | tranch		2
Convertible notes		€ 3,000		46	€ 3,000
Undrawn borrowing facilities				€ 15,000
Percentage of permissible dilution				20.00%
Closing market price | € / shares				€ 5.04
Derivatives
Disclosure Of Significant Accounting Policies [Line Items]
Number of convertible notes issued (in shares) | shares		60			60
Major ordinary share transactions | European High Growth Opportunities Securitization Fund
Disclosure Of Significant Accounting Policies [Line Items]
Number of tranches of convertible notes issued | tranch	2
Convertible notes	€ 3,000		€ 3,000
Major ordinary share transactions | Derivatives | European High Growth Opportunities Securitization Fund
Disclosure Of Significant Accounting Policies [Line Items]
Number of convertible notes issued (in shares) | shares	60		60
Top of range
Disclosure Of Significant Accounting Policies [Line Items]
Undrawn borrowing facilities				€ 33,000

Accounting Rules and Methods _2

Accounting Rules and Methods - Summary of Details of the Company's Subsidiary (Details)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Accounting Rules And Methods [Abstract]
Percent of ownership interest	100.00%

Accounting Rules and Methods _3

Accounting Rules and Methods - Summary of Accounting Policy for Exchange Rates (Details) - uSD_per_EUR	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Disclosure Of Accounting Rules And Methods [Abstract]
Weighted average rate	1.2057	1.1413	1.1015
Closing rate	1.1884	1.2271	1.1198

Accounting Rules and Methods _4

Accounting Rules and Methods - Summary of Information about Geographical Segment (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of geographical areas [line items]
Total	€ 97	€ 160
France
Disclosure of geographical areas [line items]
Total	0	61
United States
Disclosure of geographical areas [line items]
Total	€ 97	€ 99

Notes Related to the Unaudite_5

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Detailed Information of Operating Income (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Total	€ 2,270	€ 1,849
Research Tax Credit
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Total	2,132	1,674
Subsidies
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Total	41	15
Revenues from licenses or other contracts
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Total	€ 97	€ 160

Notes Related to the Unaudite_6

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)employeeshares	Jun. 30, 2020EUR (€)employee
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Outstanding equity instruments (in shares) | shares	2,220,859
Net foreign currency gain	€ 1,436	€ 542
Tedac Project
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Conditional advance received		2,979
Subsidy received		294
Research Tax Credit | Tedac Project
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Decrease in other income		€ 538
Research and development expenses
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Average number of employees | employee	155	165
General and administrative expenses
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Average number of employees | employee	41	41

Notes Related to the Unaudite_7

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Operating Expenses by Nature (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Operating Expenses [Line Items]
Total	€ 31,236	€ 37,218
Research and development expenses
Disclosure Of Operating Expenses [Line Items]
Consumables	2,196	2,761
Rental and maintenance	752	650
Services, subcontracting and fees	9,893	15,170
Personnel expenses	8,179	8,143
Depreciation, amortization & provision	2,160	2,097
Other	29	25
Total	23,209	28,846
Research and development expenses | R&D
Disclosure Of Operating Expenses [Line Items]
Consumables	82	62
Rental and maintenance	77	53
Services, subcontracting and fees	312	457
Personnel expenses	1,045	1,356
Depreciation, amortization & provision	177	106
Other	0	8
Total	1,693	2,042
Research and development expenses | Clinical studies
Disclosure Of Operating Expenses [Line Items]
Consumables	2,114	2,699
Rental and maintenance	675	597
Services, subcontracting and fees	9,581	14,713
Personnel expenses	7,134	6,787
Depreciation, amortization & provision	1,983	1,991
Other	29	17
Total	21,516	26,804
General and administrative expenses
Disclosure Of Operating Expenses [Line Items]
Consumables	94	89
Rental and maintenance	578	483
Services, subcontracting and fees	3,292	3,433
Personnel expenses	3,307	3,635
Depreciation, amortization & provision	333	341
Other	423	391
Total	€ 8,027	€ 8,372

Notes Related to the Unaudite_8

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Personal Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Research and development expenses
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	€ 5,956	€ 5,995
Share-based payments (employees and executives)	350	147
Social security expenses	1,873	2,001
Total personnel expenses	8,179	8,143
Research and development expenses | R&D
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	700	962
Share-based payments (employees and executives)	55	(38)
Social security expenses	290	432
Total personnel expenses	1,045	1,356
Research and development expenses | Clinical studies
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	5,256	5,033
Share-based payments (employees and executives)	295	185
Social security expenses	1,583	1,569
Total personnel expenses	7,134	6,787
General and administrative expenses
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	2,140	2,482
Share-based payments (employees and executives)	311	179
Social security expenses	856	974
Total personnel expenses	€ 3,307	€ 3,635

Notes Related to the Unaudite_9

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Stock-options (“SO”) plan (Details) - SO2020 € / shares in Units, € in Thousands	1 Months Ended
	Jun. 30, 2021EUR (€)sharesyear€ / shares
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Number of options granted (in shares) | shares	57,000
Exercise price (in euro per share) | € / shares	€ 4.78
Price of the underlying share (in euro per share) | € / shares	€ 4.37
Expected dividends	0.00%
Volatility	44.30%
Fair value of the plan (in thousands of euros) | €	€ 96
Tranche one
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Expected term | year	6
Tranche two
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Expected term | year	6,500

Notes Related to the Unaudit_10

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Free shares (“AGA”) plan (Details) € / shares in Units, € in Thousands	1 Months Ended	6 Months Ended
	Jun. 30, 2021EUR (€)multiplesharesyear€ / shares	Jun. 30, 2021€ / shares
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Performance criteria		Tri: (ERYPi - ERYP) / (ERYP x (PM – 1)) with ERYPi is equal to the maximum between the share price at the acquisition date and the average price of the 20-quoted market share price days before the grant date discounted by 5%•If TRi <=0% no shares granted are acquired •If Tri>100% all the shares granted are acquired •If 0%<TRi<100% shares granted are acquired following the TRi percentage
AGA 2020
Disclosure Of Detailed Information Of Operating Income Loss [Line Items]
Number of options granted (in shares) | shares	50,831
Price of the underlying share (in euro per share)	€ 4.37	€ 4.37
Expected dividends	0.00%
Volatility	44.79%
Repo margin	5.00%
Expected term | year	5
Weighted average share price, share options granted (in euro per share)	€ 4.78
Performance multiple ("PM") | multiple	2
Fair value of the plan (in thousands of euros) | €	€ 121

Notes Related to the Unaudit_11

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Breakdown of Plan (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	€ 707	€ 384
Employees
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	268	166
Executives
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	436	189
Directors
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	1	29
AGA
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	308	167
AGA | Employees
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	161	120
AGA | Executives
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	146	47
BSA
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	1	29
BSA | Directors
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	1	29
SO
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	398	188
SO | Employees
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	107	46
SO | Executives
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Share-based compensation expense recognized in profit (loss)	€ 290	€ 142

Notes Related to the Unaudit_12

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Financial Income (Loss) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
Income from short term deposits	€ 11	€ 3
Change in fair value of derivative liabilities	750	0
Other financial income	2,046	669
Financial income	2,807	672
Amortized cost of convertible notes	(919)	0
Financial expenses on lease liability	(156)	(178)
Interest expense related to borrowings	(158)	(54)
Other financial expenses	(558)	(33)
Financial expenses	(1,791)	(265)
Financial income (loss)	€ 1,016	€ 407

Notes Related to the Unaudit_13

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Income (Loss) - Summary of Basic Earnings per Share and Diluted Earnings (Loss) per Share (Details) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
Net loss	€ (27,952)	€ (34,962)
Weighted number of shares for the period (in shares)	22,842,857	17,942,117
Basic loss per share (€/share)	€ (1.22)	€ (1.95)
Diluted loss per share (€/share)	€ (1.22)	€ (1.95)
Number of treasury shares held (in shares)	2,500,000	2,500,000

Notes Related to the Unaudit_14

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Schedule of Property, Plant and Equipment (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	€ 20,862
Ending balance	19,818
GROSS VALUE
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	27,769
Increase	94
Decrease	(9)
FX rate impact	684
Reclassification	22
Ending balance	28,560
ACCUMULATED DEPRECIATION
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(6,907)
Decrease	9
FX rate impact	(133)
Reclassification	0
Increase	(1,711)
Ending balance	(8,742)
General equipment, fixtures and fittings
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	16,574
Ending balance	16,011
General equipment, fixtures and fittings | GROSS VALUE
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	20,701
Increase	25
Decrease	0
FX rate impact	580
Reclassification	0
Ending balance	21,306
General equipment, fixtures and fittings | ACCUMULATED DEPRECIATION
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(4,127)
Decrease	0
FX rate impact	(102)
Reclassification	0
Increase	(1,066)
Ending balance	(5,295)
Plant, equipment and tooling
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	3,695
Ending balance	3,226
Plant, equipment and tooling | GROSS VALUE
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	5,787
Increase	0
Decrease	0
FX rate impact	91
Reclassification	0
Ending balance	5,878
Plant, equipment and tooling | ACCUMULATED DEPRECIATION
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(2,092)
Decrease	0
FX rate impact	(25)
Reclassification	0
Increase	(535)
Ending balance	(2,652)
Office equipment and computers
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	516
Ending balance	493
Office equipment and computers | GROSS VALUE
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,204
Increase	16
Decrease	(9)
FX rate impact	13
Reclassification	64
Ending balance	1,288
Office equipment and computers | ACCUMULATED DEPRECIATION
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(688)
Decrease	9
FX rate impact	(6)
Reclassification	0
Increase	(110)
Ending balance	(795)
Assets under construction
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	77
Ending balance	66
Assets under construction | GROSS VALUE
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	77
Increase	42
Decrease	0
FX rate impact	0
Reclassification	(53)
Ending balance	66
Assets under construction | ACCUMULATED DEPRECIATION
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Decrease	0
FX rate impact	0
Reclassification	0
Increase	0
Ending balance	0
Advance payment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Ending balance	22
Advance payment | GROSS VALUE
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Increase	11
Decrease	0
FX rate impact	0
Reclassification	11
Ending balance	22
Advance payment | ACCUMULATED DEPRECIATION
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Decrease	0
FX rate impact	0
Reclassification	0
Increase	0
Ending balance	€ 0

Notes Related to the Unaudit_15

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Schedule of Right of Use (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	€ 8,228
Ending balance	7,278
GROSS VALUE
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	11,991
Increase	379
Decrease	(1,715)
FX rate impact	150
Reclassification	0
Ending balance	10,805
ACCUMULATED DEPRECIATION
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	(3,763)
Decrease	1,050
FX rate impact	(39)
Reclassification	0
Increase	(775)
Ending balance	(3,527)
Buildings
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	8,197
Ending balance	6,913
Buildings | GROSS VALUE
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	10,846
Increase	0
Decrease	(1,715)
FX rate impact	145
Reclassification	0
Ending balance	9,276
Buildings | ACCUMULATED DEPRECIATION
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	(2,649)
Decrease	1,050
FX rate impact	(38)
Reclassification	0
Increase	(726)
Ending balance	(2,363)
Plant, equipment and tooling
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	0
Ending balance	343
Plant, equipment and tooling | GROSS VALUE
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	954
Increase	376
Decrease	0
FX rate impact	5
Reclassification	0
Ending balance	1,335
Plant, equipment and tooling | ACCUMULATED DEPRECIATION
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	(954)
Decrease	0
FX rate impact	(1)
Reclassification	0
Increase	(37)
Ending balance	(992)
Transport equipment
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	31
Ending balance	22
Transport equipment | GROSS VALUE
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	73
Increase	3
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	76
Transport equipment | ACCUMULATED DEPRECIATION
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	(42)
Decrease	0
FX rate impact	0
Reclassification	0
Increase	(12)
Ending balance	(54)
Office equipment and computers
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	0
Ending balance	0
Office equipment and computers | GROSS VALUE
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	118
Increase	0
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	118
Office equipment and computers | ACCUMULATED DEPRECIATION
Disclosure Of Detailed information Of Right Of Use [Line Items]
Beginning balance	(118)
Decrease	0
FX rate impact	0
Reclassification	0
Increase	0
Ending balance	€ (118)

Notes Related to the Unaudit_16

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Schedule of Trade Receivables and Other Current Assets (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Detailed Information Of Financial Position [Abstract]
Trade and other receivables	€ 14	€ 4
Research Tax Credit	5,564	3,432
Other receivables (including tax and social receivables)	660	898
Net investment in a sublease	446	0
Prepaid expenses	1,515	793
Total other current assets	€ 8,185	€ 5,123

Notes Related to the Unaudit_17

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Additional Information (Details) € / shares in Units, € in Thousands, $ in Millions		1 Months Ended			3 Months Ended	6 Months Ended
		Apr. 30, 2021EUR (€)shares	Feb. 28, 2021EUR (€)shares	Feb. 28, 2021USD ($)shares	May 19, 2021EUR (€)tranch	Jun. 30, 2021EUR (€)€ / sharesshares		Jun. 30, 2020EUR (€)	Mar. 02, 2021EUR (€)	Dec. 31, 2020EUR (€)shares
Disclosure of quantitative information about right-of-use assets [line items]
Prepaid expenses						€ 1,515				€ 793
Term deposits						€ 5,102				€ 10,098
Number of shares fully paid up (in shares) | shares						26,438,955				20,057,562
Nominal value (in euro per share) | € / shares						€ 0.10
Capital increases, net of transaction costs						€ 29,320		€ 118
Issue of ordinary shares						39,834	[1]	€ 119
Share issue related cost	[2]					2,655
Number of tranches of borrowings issued | tranch					2
Convertible notes					€ 3,000	€ 46			€ 3,000
Number of convertible notes converted (in shares) | shares						167
Conversion of convertible notes ("OCA") (in shares) | shares						1,493,320
Number of convertible notes outstanding (in shares) | shares						1
Number of warrants attached to convertible notes outstanding (in shares) | shares						235,690
Hospital costs accruals						€ 10,557				€ 10,770
At-The-Market Offering
Disclosure of quantitative information about right-of-use assets [line items]
Number of shares issued during the period | shares			744,186	744,186		744,186
Capital increases, net of transaction costs			€ 6,400
Issue of ordinary shares			€ 6,600	$ 8		€ 6,616
Share issue related cost						€ 241
Registered Offering
Disclosure of quantitative information about right-of-use assets [line items]
Number of shares issued during the period | shares		4,137,932				4,137,932
Capital increases, net of transaction costs		€ 22,500
Issue of ordinary shares		€ 24,900				€ 24,869
Share issue related cost						€ 2,414
Tranche six
Disclosure of quantitative information about right-of-use assets [line items]
Convertible notes									€ 3,000
Tranche seven
Disclosure of quantitative information about right-of-use assets [line items]
Convertible notes					€ 3,000
Financial liabilities at amortised cost, category | Tranche Six And Seven
Disclosure of quantitative information about right-of-use assets [line items]
Borrowings, interest rate						13.00%
Term Deposits
Disclosure of quantitative information about right-of-use assets [line items]
Term deposits						€ 5,000				10,000
Convertible to cash
Disclosure of quantitative information about right-of-use assets [line items]
Term deposits						100				€ 100
Directors and Officers
Disclosure of quantitative information about right-of-use assets [line items]
Prepaid expenses						€ 1,026
[1]	Includes €24,869 thousand related to the Registered Offering, €6,616 thousand to shares sold under the at-the-market (“ATM”) program (refer to note 4.5) and €8,350 thousand linked to the conversion of convertible notes (refer to note 4.6.1).
[2]	Includes €2,414 thousand related to the Registered Offering and €241 thousand to shares sold under the at-the-market (“ATM”) program.

Notes Related to the Unaudit_18

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Disclosure Of Detailed Information Of Financial Position [Abstract]
Current account	€ 41,221	€ 34,348
Term deposits	5,102	10,098
Total cash and cash equivalents as reported in statement of financial position	46,323	44,446
Bank overdrafts	0	0
Total cash and cash equivalents as reported in statement of cash flow	€ 46,323	€ 44,446	€ 45,433	€ 73,173

Notes Related to the Unaudit_19

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Shareholders' Equity (Details) - shares	1 Months Ended		6 Months Ended
	Apr. 30, 2021	Feb. 28, 2021	Jun. 30, 2021
Disclosure of classes of share capital [line items]
Beginning balance (in shares)			20,057,562
Conversion of convertible notes ("OCA") (in shares)			1,493,320
Free shares acquired (in shares)			5,955
Ending balance (in shares)			26,438,955
Registered Offering
Disclosure of classes of share capital [line items]
Number of shares issued during the period	4,137,932		4,137,932
At-The-Market Offering
Disclosure of classes of share capital [line items]
Number of shares issued during the period		744,186	744,186

Notes Related to the Unaudit_20

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Financial Liabilities by Type (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	€ 16,644
Collection	5,712	€ 2,979
Fair value of embedded derivatives	(404)
Amortized cost	1,077
Conversion	(8,350)
Repayment	0	€ (62)
FX rate impact	2
Liabilities arising from financing activities at end of period	14,681
Convertible notes
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	2,169
Collection	5,712
Fair value of embedded derivatives	(404)
Amortized cost	919
Conversion	(8,350)
Repayment	0
FX rate impact	0
Liabilities arising from financing activities at end of period	46
Conditional advances
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	4,421
Collection	0
Amortized cost	66
Repayment	0
FX rate impact	0
Liabilities arising from financing activities at end of period	4,487
Bank loans
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	10,019
Collection	0
Amortized cost	92
Repayment	0
FX rate impact	0
Liabilities arising from financing activities at end of period	10,111
Other
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	35
Collection	0
Amortized cost	0
Repayment	0
FX rate impact	2
Liabilities arising from financing activities at end of period	€ 37

Notes Related to the Unaudit_21

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Financial Liabilities by Maturity (Details) - EUR (€) € in Thousands	Jun. 30, 2021	May 19, 2021	Mar. 02, 2021
Disclosure of financial liabilities [line items]
Convertible notes	€ 46	€ 3,000	€ 3,000
Conditional advances	4,487
Bank loans	10,111
Other	37
Total financial liabilities	14,681
Less than one year
Disclosure of financial liabilities [line items]
Convertible notes	46
Conditional advances	0
Bank loans	182
Other	0
Total financial liabilities	228
One to three years
Disclosure of financial liabilities [line items]
Convertible notes	0
Conditional advances	0
Bank loans	3,526
Other	37
Total financial liabilities	3,563
Three to five years
Disclosure of financial liabilities [line items]
Convertible notes	0
Conditional advances	0
Bank loans	5,099
Other	0
Total financial liabilities	5,099
More than five years
Disclosure of financial liabilities [line items]
Convertible notes	0
Conditional advances	4,487
Bank loans	1,304
Other	0
Total financial liabilities	€ 5,791

Notes Related to the Unaudit_22

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Derivative Financial Instruments (Details) - EUR (€) € / shares in Units, € in Thousands	Jun. 30, 2021	May 19, 2021	Mar. 02, 2021	Dec. 31, 2020
Disclosure of fair value measurement of liabilities [line items]
Number of convertible notes outstanding (in shares)	1
Fair value (in thousands of euros)	€ 3			€ 129
Number of warrants attached to convertible notes outstanding (in shares)	235,690
Fair value (in thousands of euros)	€ 69			€ 288
Convertible notes | Derivatives
Disclosure of fair value measurement of liabilities [line items]
Number of convertible notes outstanding (in shares)	1			48
Estimated conversion price (in euro per share)	€ 3.73			€ 6.75
Expected term	1 day			1 month
Fair value (in thousands of euros)	€ 3			€ 129
Convertible notes | Derivatives | Tranche six
Disclosure of fair value measurement of liabilities [line items]
Number of convertible notes (in shares)			60
Estimated conversion price (in euro per share)			€ 6.94
Expected term			1 month
Fair value (in thousands of euros)			€ 160
Convertible notes | Derivatives | Tranche seven
Disclosure of fair value measurement of liabilities [line items]
Number of convertible notes (in shares)		60
Estimated conversion price (in euro per share)		€ 4.87
Expected term		1 month
Fair value (in thousands of euros)		€ 160
Warrants | Derivatives
Disclosure of fair value measurement of liabilities [line items]
Expected term	1 year 6 months			2 years
Number of warrants attached to convertible notes outstanding (in shares)	235,690			168,350
Price of the underlying share (in euro per share)	€ 3.93			€ 7.11
Expected dividends	0.00%			0.00%
Volatility	61.13%			58.11%
Fair value (in thousands of euros)	€ 69			€ 288
Warrants | Derivatives | Tranche six
Disclosure of fair value measurement of liabilities [line items]
Expected term			1 year 10 months
Number of warrants (in shares)			33,670
Price of the underlying share (in euro per share)			€ 7.30
Expected dividends			0.00%
Volatility			58.40%
Fair value (in thousands of euros)			€ 59
Warrants | Derivatives | Tranche seven
Disclosure of fair value measurement of liabilities [line items]
Expected term		1 year 7 months
Number of warrants (in shares)		33,670
Price of the underlying share (in euro per share)		€ 5.13
Expected dividends		0.00%
Volatility		62.24%
Fair value (in thousands of euros)		€ 25

Notes Related to the Unaudit_23

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Sensitivity Analysis for the Valuation of Warrants (Details) € in Thousands	Jun. 30, 2021EUR (€)€ / shares	Dec. 31, 2020EUR (€)
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Derivative liabilities - non current portion	€ 69	€ 288
Price of underlying share
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Price of underlying share (euro per share) | € / shares	3.93
Derivatives | Warrants
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Fair value of warrants if underlying share price decrease by 10% and volatility decrease by 10 percentage points	€ 25
Fair value of warrants if volatility decrease by 10 percentage points	38
Fair value of warrants if underlying share price decrease by 10% and volatility increase by 10 percentage points	54
Fair value of warrants if underlying share price decrease by 10%	49
Derivative liabilities - non current portion	69	€ 288
Fair value of warrants if underlying share price increase by 10%	93
Fair value of warrants if underlying share price increase by 10% and volatility decrease by 10 percentage points	80
Fair value of warrants if volatility increase by 10 percentage points	107
Fair value of warrants if underlying share price increase by 10% and volatility increase by 10 percentage points	€ 137

Notes Related to the Unaudit_24

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Schedule of Lease Liabilities (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Detailed Information Of Financial Position [Abstract]
Lease liabilities at beginning of the year	€ 10,804
Increase without cash impact	379
Repayment	(830)	€ (810)
Decrease without cash impact	0
FX rate impact	194
Capitalized interests	0
Lease liabilities at end of the year	€ 10,547

Notes Related to the Unaudit_25

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Lease Liabilities By Maturity (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	€ 10,547	€ 10,804
Less than one year
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	1,732
One to three years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	2,965
Three to five years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	2,276
More than five years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	€ 3,574

Notes Related to the Unaudit_26

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Trade Payables and Other Current Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Detailed Information Of Financial Position [Abstract]
Vendors	€ 3,352	€ 4,706
Vendors - accruals	14,287	16,204
Total trade and other payables	17,639	20,910
Social liabilities, taxation and social security	3,604	4,149
Fixed assets payables	33	86
Deferred revenue	120	148
Other payables	69	53
Total other current liabilities	€ 3,826	€ 4,436

Notes Related to the Unaudit_27

Notes Related to the Unaudited Interim Condensed Consolidated Statement of Financial Position - Summary of Financial Instruments Recognized in the Consolidated Statement of Financial Position and Effect on Net Income (Loss) (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of financial instruments [line items]
Other non-current assets	€ 1,091	€ 1,091
Trade and other receivables	14	4
Other current assets	8,185	5,123
Cash and cash equivalents	46,323	44,446
Financial liabilities – non-current portion	14,452	14,379
Derivative liabilities - non current portion	69	288
Lease liabilities - non-current portion	8,815	9,197
Financial liabilities – current portion	229	2,265
Derivative liabilities - current portion	3	129
Lease liabilities - current portion	1,732	1,607
Trade and other payables	17,639	20,910
Other current liabilities	3,826	4,436
Total financial liabilities	14,681
Financial liabilities at carrying value, category
Disclosure of financial instruments [line items]
Financial liabilities – non-current portion	14,452	14,379
Derivative liabilities - non current portion	69	288
Lease liabilities - non-current portion	8,815	9,197
Financial liabilities – current portion	229	2,265
Derivative liabilities - current portion	3	129
Lease liabilities - current portion	1,732	1,607
Trade and other payables	17,639	20,910
Other current liabilities	3,706	4,288
Total financial liabilities	46,645	53,063
Financial liabilities at fair value through profit or loss, category
Disclosure of financial instruments [line items]
Derivative liabilities - non current portion	69	288
Derivative liabilities - current portion	3	129
Total financial liabilities	72	417
Financial liabilities at amortised cost, category
Disclosure of financial instruments [line items]
Financial liabilities – non-current portion	14,452	14,379
Lease liabilities - non-current portion	8,815	9,197
Financial liabilities – current portion	229	2,265
Lease liabilities - current portion	1,732	1,607
Trade and other payables	17,639	20,910
Other current liabilities	3,706	4,288
Total financial liabilities	46,573	52,646
Financial liabilities at fair value, class
Disclosure of financial instruments [line items]
Financial liabilities – non-current portion	14,452	14,379
Derivative liabilities - non current portion	69	288
Lease liabilities - non-current portion	8,815	9,197
Financial liabilities – current portion	229	2,265
Derivative liabilities - current portion	3	129
Lease liabilities - current portion	1,732	1,607
Trade and other payables	17,639	20,910
Other current liabilities	3,706	4,288
Total financial liabilities	46,645	53,063
Financial assets at carrying value, category
Disclosure of financial instruments [line items]
Other non-current assets	1,091	1,091
Other current financial assets	516	59
Trade and other receivables	14	4
Other current assets	6,669	4,330
Cash and cash equivalents	46,323	44,446
Total financial assets	54,613	49,930
Financial assets at fair value through profit or loss, category
Disclosure of financial instruments [line items]
Cash and cash equivalents	46,323	44,446
Total financial assets	46,323	44,446
Financial assets at amortised cost, category
Disclosure of financial instruments [line items]
Other non-current assets	1,091	1,091
Other current financial assets	516	59
Trade and other receivables	14	4
Other current assets	6,669	4,330
Total financial assets	8,290	5,484
Financial assets at fair value, class
Disclosure of financial instruments [line items]
Other non-current assets	1,091	1,091
Other current financial assets	516	59
Trade and other receivables	14	4
Other current assets	6,669	4,330
Cash and cash equivalents	46,323	44,446
Total financial assets	€ 54,613	€ 49,930

Related Parties - Summary of Tr

Related Parties - Summary of Transactions Between Related Parties (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of transactions between related parties [line items]
Salary / fees	€ 1,510	€ 1,379
Retirement benefits	23	22
Share based payments	438	219
Executive officers / VP and qualified person
Disclosure of transactions between related parties [line items]
Salary / fees	593	639
Retirement benefits	11	11
Share based payments	254	171
Executive committee
Disclosure of transactions between related parties [line items]
Salary / fees	764	593
Retirement benefits	12	11
Share based payments	183	19
Board of directors
Disclosure of transactions between related parties [line items]
Salary / fees	153	147
Retirement benefits	0	0
Share based payments	€ 1	€ 29

Off-Balance Sheet Commitments (

Off-Balance Sheet Commitments (Details) $ in Thousands	1 Months Ended
	May 31, 2021USD ($)
United States
Disclosure of quantitative information about right-of-use assets [line items]
Finance sublease, security deposit received	$ 59